---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-009179"
form_type: "8-K"
ticker: "CVM"
cik: "0000725363"
company_name: "CEL SCI CORP"
filed_at: "2023-07-14T23:59:59+00:00"
generated_at: "2026-06-13T08:30:22.435884+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# CEL-SCI reports positive FDA meeting for Multikine approval; Canada possible 2024

## Summary
- FDA acknowledged need for improved head/neck cancer treatments; CEL-SCI preparing further development plan.
- Multikine showed 14.1% absolute OS benefit in lower-risk ITT subjects; 15.2% tumor response in 3 weeks.
- Health Canada advised NOCC application; commercialization in Canada could begin as early as 2024.
- Upcoming scientific advice meetings with EMA and MHRA in fall 2023.
- CEL-SCI plans to file NOCC application in Canada later this year/early next year.

## SEC filing metadata
- accession: 0001654954-23-009179
- form_type: 8-K
- ticker: CVM
- cik: 0000725363
- company_name: CEL SCI CORP
- filed_at: 2023-07-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/725363/000165495423009179/0001654954-23-009179-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/725363/000165495423009179/cvm_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-009179
- JSON: https://secwatch.observer/filing/0001654954-23-009179.json
- Plain text: https://secwatch.observer/filing/0001654954-23-009179.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.